Matthew O'Brien
Stock Analyst at Piper Sandler
(2.55)
# 2,216
Out of 4,711 analysts
29
Total ratings
68.75%
Success rate
8.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $140 → $115 | $107.12 | +7.36% | 12 | Jul 1, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $17 | $9.35 | +81.82% | 3 | May 8, 2024 | |
| PODD Insulet | Maintains: Neutral | $295 → $230 | $266.57 | -13.72% | 1 | Feb 24, 2022 | |
| KRMD KORU Medical Systems | Downgrades: Neutral | $9 → $4.5 | $4.02 | +11.94% | 1 | Jan 26, 2021 | |
| IART Integra LifeSciences Holdings | Maintains: Neutral | $53 → $47 | $21.80 | +115.60% | 8 | Oct 29, 2020 | |
| BAX Baxter International | Maintains: Overweight | $77 → $83 | $29.50 | +181.36% | 1 | Jul 27, 2018 | |
| ALGN Align Technology | Maintains: Overweight | $300 → $325 | $211.06 | +53.98% | 1 | May 24, 2018 | |
| DXCM DexCom | Reinstates: Overweight | $20 | $80.04 | -75.64% | 1 | May 22, 2017 | |
| MDXG MiMedx Group | Initiates: Overweight | $10 | $9.10 | +9.89% | 1 | Mar 3, 2017 |
Zimmer Biomet Holdings
Jul 1, 2024
Downgrades: Neutral
Price Target: $140 → $115
Current: $107.12
Upside: +7.36%
Alphatec Holdings
May 8, 2024
Maintains: Overweight
Price Target: $19 → $17
Current: $9.35
Upside: +81.82%
Insulet
Feb 24, 2022
Maintains: Neutral
Price Target: $295 → $230
Current: $266.57
Upside: -13.72%
KORU Medical Systems
Jan 26, 2021
Downgrades: Neutral
Price Target: $9 → $4.5
Current: $4.02
Upside: +11.94%
Integra LifeSciences Holdings
Oct 29, 2020
Maintains: Neutral
Price Target: $53 → $47
Current: $21.80
Upside: +115.60%
Baxter International
Jul 27, 2018
Maintains: Overweight
Price Target: $77 → $83
Current: $29.50
Upside: +181.36%
Align Technology
May 24, 2018
Maintains: Overweight
Price Target: $300 → $325
Current: $211.06
Upside: +53.98%
DexCom
May 22, 2017
Reinstates: Overweight
Price Target: $20
Current: $80.04
Upside: -75.64%
MiMedx Group
Mar 3, 2017
Initiates: Overweight
Price Target: $10
Current: $9.10
Upside: +9.89%